Castillo J, et al. – A randomized clinical trial was done to evaluate the optimal interval of preoperative intravitreal bevacizumab (IVB) administration in diabetic subjects going through pars plana vitrectomy (PPV) for severe manifestations of active proliferative diabetic retinopathy (PDR). These outcomes exhibited better postoperative outcomes at 6 months when subjects received preoperative IVB 5–10 days before PPV compared to 1–3 days for the treatment of PDR–related complications.